Cannabis and MS: Efficacy, Safety, Drug Interactions, and Research Update
Allen Bowling, MD, PhD
RELEASE DATE: May 28, 2020
EXPIRATION DATE: May 31, 2021
TIME TO COMPLETE THE ACTIVITY: 1 hour
This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, psychologists, social workers, rehabilitation specialists, researchers, advocates, and other members of the healthcare team involved in the management of patients with MS, conduct research in MS or who have a special interest in MS.
- Describe 2 potential therapeutic effects of cannabis
- Describe 2 potential side effects of cannabis
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this enduring material for 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for 1.0 contact hour of continuing nursing education.
This knowledge-based activity (UAN # JA4008165-0000-20-016-H01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until May 31, 2021. PAs should only claim credit commensurate with the extent of their participation.
This activity is awarded 1.0 CE credits.
As a Jointly Accredited Organization, the Consortium of Multiple Sclerosis Centers (CMSC) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CMSC maintains responsibility for this course. Social workers completing this course receive 1.0 continuing education credit
CERTIFICATE OF ATTENDANCE FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Attendance will be given upon completion of course requirements enabling attendees to register their credit with the appropriate licensing boards or associations. Attendees may apply for other accreditations using procedures established by specific organizations.
DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of CMSC to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
Allen Bowling, MD, PhD has disclosed the following relevant financial relationships: Royalty: Springer Publishing; Consulting Fee: Celgene/Bristol Myers Squibb, EMD Serono, Inc., Novartis Pharmaceuticals Corporation, Greenwich Biosciences; Speakers Bureau: Celgene/Bristol Myers Squibb, EMD Serono, Inc., Genentech, Novartis Pharmaceuticals Corporation, Sanofi Genzyme, Greenwich Biosciences.
PLANNERS, REVIEWERS AND STAFF DISCLOSURES
Corey C. Ford, MD, PhD (Planner) has disclosed the following relevant financial relationship(s): Consulting Fee: Teva Pharmaceuticals, GW Pharma, and Actelion; Contracted Research: Actelion, Adamas, Alkermes, Biogen, Genentech, Genzyme, Mallinckrodt, Medday, Novartis, Roche, Sanofi Aventis, Teva Pharmaceuticals, and TG Therapeutics.
June Halper, MSN, APN-C, MSCN, FAAN (Planner and Reviewer) has disclosed no relevant financial relationships.
Colleen Harris, MN, NP, MSCN (Planner) has disclosed the following relevant financial relationship(s): Consulting Fee: Biogen, Roche, Merck, Sanofi Genzyme, and Novartis Pharmaceuticals Corp.
Laurie Scudder, DNP, NP (Reviewer) has disclosed no relevant financial relationships.
Tina Trott and the staff at CMSC have disclosed no relevant financial relationships.
There is no fee to participate in these educational activities.
INSTRUCTIONS FOR PARTICIPATION AND OBTAINING CREDIT
In order to successfully complete this knowledge-based continuing education activity, participants must:
1) Read the learning objectives and disclosures.
2) Study/view the educational content.
3) Complete the online evaluation form.
To complete the evaluation and claim credit, go to www.highmarksce.com/mscare/
1) Create a new account or log in with your user name and password*.
2) Select the Enduring Materials tab, select the activity from the list and follow the instructions to complete the activity and receive your credit.
*If you forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.
For credit claiming assistance, please contact [email protected] .
COMPUTER SYSTEM REQUIREMENTS
It is recommended that you use the latest version of Microsoft Edge, Chrome, Safari, or Firefox to view this activity.
DISCLOSURE OF UNLABELED USE
CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC assumes no liability for the information herein.
For information about the accreditation of this program, please contact the CMSC at [email protected].